Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell

Immunology

Volumn 126, Issue 3, 2009, Pages 423-435

  Linn, Yeh C ^b   Lau, Siew Kee J ^a   Liu, Bee H ^a   Ng, Lee H ^b   Yong, Hao X ^b   Hui, Kam M ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Adoptive cellular immunotherapy; Cytokine induced killer cells; Natural killer receptors; Natural killer like T cells; Non major histocompatibility complex restricted T cells

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD56 ANTIGEN; CYTOKINE; GRANZYME A; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; NKG2C PROTEIN; NKG2E PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; KILLER CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; NATURAL KILLER T CELL; NORMAL DISTRIBUTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; T LYMPHOCYTE SUBPOPULATION; TARGET CELL;

ANTIGENS, CD3; ANTIGENS, CD56; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED;

EID: 59449109417     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02910.x     Document Type: Article

References (34)

1. Schmidt-Wolf IGH, Lefterova P, Johnston V et al. Sensitivity of multidrug-resistant tumour cell lines to immunologic effector cells. Cell Immunol 1996 169 : 85 90.
2. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994 153 : 1687 96.
3. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukemic samples with in vitro cytotoxicity against autologous and allogeneic leukemic blasts. Br J Hematol 2002 116 : 78 86.
4. Schmidt-Wolf IGH, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumour cell activity. J Exp Med 1991 174 : 139 49.
5. + cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998 92 : 3318 27.
6. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003 101 : 640 8.
7. Schmidt-Wolf IGH, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumour cell recognition of cytokine-induced killer cells. Exp Hematol 1993 21 : 1673 9.
8. Ziske C, Marten A, Schottker B et al. Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumour-derived RNA and CA 19-9. Mol Ther 2001 3 : 54 60.
9. Marten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowlki F, Glasmacher A, Sauerbruch T, Schmidt-Wolf IGH. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 2001 86 : 1029 37.
10. + natural killer T cells with limited capacity for graft vs host disease induction due to interferon γ production. Blood 2001 97 : 2923 31.
11. +cells from peripheral blood progenitor cells of patients undergoing autologous haemopoietic cell transplant. Biol Blood Marrow Transplant 2001 7 : 216 22.
12. Schmidt-Wolf IGH, Finke S, Trojaneck B et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999 81 (6 1009 16.
13. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin's disease and non Hodgkin's lymphoma. Biol Blood Marrow Transplant 2005 11 : 181 7.
14. Jiang H, Lu K, Tong C, Jiang K, Lu D. The efficacy of chemotherapy combination with auto-cytokine-induced killer cells in acute leukemia. Chin J Intern Med 2005 44 : 198 201.
15. Gorski J, Yassai M, Zhu X, Kissella B, Keever C, Flomenberg N. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDr3 size spectratyping. Correlation with immune status. J Immunol 1994 152 : 5109 19.
16. Lang P, Barbin K, Feuchtinger T et al. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood 2004 103 : 3982 5.
17. Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myeloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol 2005 33 : 671 81.
18. Zhong R-K, Rassenti LZ, Kipps TJ, Chen J, Law P, Yu J-F, Ball ED. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. Biol Blood Marrow Transplant 2002 8 : 557 68.
19. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989 86 : 7159 65.
20. Blander JM, Ciboroski P, Hsia S, Watkins SC, Finn OJ. Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol 1998 160 : 3111 20.
21. Nehad MA, Schmielau J, Alter MD, Cascio M, Finn OJ. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood 2005 105 : 4583 9.
22. Brossart P, Schneider A, Dill P et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001 61 : 6846 50.
23. Derre L, Corvaisier M, Pandolfino MC, Diez E, Jotereau F, Gervois N. Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. J Immunol 2002 168 : 4864 70.
24. + T cells. Blood 2004 103 : 3065 72.
25. Chan JK, Hamilton CA, Cheung MK et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 2006 12 : 1859 67.
26. Pende D, Rivera P, Marcenaro S et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different hstiotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002 62 : 6178 86.
27. Pende D, Spaggiari GM, Marcenaro S et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor (CD155) and Nectin-2(CD112). Blood 2005 105 : 2066 73.
28. Shibuya A, Campbell D, Hannum C et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996 4 : 573 81.
29. - natural killer T cells specific for MUC 1 mucin. Cancer Res 2004 64 : 1171 80.
30. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005 105 : 241 50.
31. + T cells. J Clin Invest 2005 115 : 1616 26.
32. + T cells. J Clin Invest 2005 115 : 1467 9.
33. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002 110 : 185 92.
34. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005 23 : 2346 57.